ALS/FTLD: experimental models and reality

被引:0
|
作者
Rachel H. Tan
Yazi D. Ke
Lars M. Ittner
Glenda M. Halliday
机构
[1] Neuroscience Research Australia,School of Medical Sciences
[2] University of NSW,Brain and Mind Centre, Sydney Medical School
[3] the University of Sydney,Motor Neuron Disease Unit, Department of Anatomy, Faculty of Medicine
[4] University of NSW,Dementia Research Unit, Department of Anatomy, Faculty of Medicine
[5] University of NSW,undefined
来源
Acta Neuropathologica | 2017年 / 133卷
关键词
Amyotrophic lateral sclerosis; C9orf72; Frontotemporal lobar degeneration; Microtubule associated protein tau; Superoxide dismutase 1; tar DNA-binding protein 43;
D O I
暂无
中图分类号
学科分类号
摘要
Amyotrophic lateral sclerosis is characterised by a loss of upper and lower motor neurons and characteristic muscle weakness and wasting, the most common form being sporadic disease with neuronal inclusions containing the tar DNA-binding protein 43 (TDP-43). Frontotemporal lobar degeneration is characterised by atrophy of the frontal and/or temporal lobes, the most common clinical form being the behavioural variant, in which neuronal inclusions containing either TDP-43 or 3-repeat tau are most prevalent. Although the genetic mutations associated with these diseases have allowed various experimental models to be developed, the initial genetic forms identified remain the most common models employed to date. It is now known that these first models faithfully recapitulate only some aspects of these diseases and do not represent the majority of cases or the most common overlapping pathologies. Newer models targeting the main molecular pathologies are still rare and in some instances, lack significant aspects of the molecular pathology. However, these diseases are complex and multigenic, indicating that experimental models may need to be targeted to different disease aspects. This would allow information to be gleaned from a variety of different yet relevant models, each of which has the capacity to capture a certain aspect of the disease, and together will enable a more complete understanding of these complex and multi-layered diseases.
引用
收藏
页码:177 / 196
页数:19
相关论文
共 50 条
  • [31] Towards a TDP-43-Based Biomarker for ALS and FTLD
    Emily Feneberg
    Elizabeth Gray
    Olaf Ansorge
    Kevin Talbot
    Martin R. Turner
    Molecular Neurobiology, 2018, 55 : 7789 - 7801
  • [32] Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD
    Emily Feneberg
    Petra Steinacker
    Alexander Erich Volk
    Jochen Hans Weishaupt
    Marc Axel Wollmer
    Adam Boxer
    Hayrettin Tumani
    Albert Christian Ludolph
    Markus Otto
    Journal of Neural Transmission, 2016, 123 : 289 - 296
  • [33] Codon-optimized TDP-43 mediates neurodegeneration in a Drosophila model of ALS/FTLD
    Yusuff, Tanzeen
    Chang, Ya-Chu
    Sang, Tzu-Kang
    Jackson, George R.
    Chatterjee, Shreyasi
    FRONTIERS IN GENETICS, 2023, 14
  • [34] RNA-binding proteins with prion-like domains in ALS and FTLD-U
    Gitler, Aaron D.
    Shorter, James
    PRION, 2011, 5 (03) : 179 - 187
  • [35] Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum
    Cruts, Marc
    Gijselinck, Ilse
    Van Langenhove, Tim
    van der Zee, Julie
    Van Broeckhoven, Christine
    TRENDS IN NEUROSCIENCES, 2013, 36 (08) : 450 - 459
  • [36] RNA Granules and Diseases: A Case Study of Stress Granules in ALS and FTLD
    Fan, Alexander C.
    Leung, Anthony K. L.
    RNA PROCESSING: DISEASE AND GENOME-WIDE PROBING, 2016, 907 : 263 - 296
  • [37] NUP62 localizes to ALS/FTLD pathological assemblies and contributes to TDP-43 insolubility
    Gleixner, Amanda M.
    Verdone, Brandie Morris
    Otte, Charlton G.
    Anderson, Eric N.
    Ramesh, Nandini
    Shapiro, Olivia R.
    Gale, Jenna R.
    Mauna, Jocelyn C.
    Mann, Jacob R.
    Copley, Katie E.
    Daley, Elizabeth L.
    Ortega, Juan A.
    Cicardi, Maria Elena
    Kiskinis, Evangelos
    Kofler, Julia
    Pandey, Udai B.
    Trotti, Davide
    Donnelly, Christopher J.
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [38] Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion
    Brettschneider, Johannes
    Van Deerlin, Vivianna M.
    Robinson, John L.
    Kwong, Linda
    Lee, Edward B.
    Ali, Yousuf O.
    Safren, Nathaniel
    Monteiro, Mervyn J.
    Toledo, Jon B.
    Elman, Lauren
    McCluskey, Leo
    Irwin, David J.
    Grossman, Murray
    Molina-Porcel, Laura
    Lee, Virginia M. -Y.
    Trojanowski, John Q.
    ACTA NEUROPATHOLOGICA, 2012, 123 (06) : 825 - 839
  • [39] mTh1 driven expression of hTDP-43 results in typical ALS/FTLD neuropathological symptoms
    Scherz, Barbara
    Rabl, Roland
    Flunkert, Stefanie
    Rohler, Siegfried
    Neddens, Joerg
    Taub, Nicole
    Temmel, Magdalena
    Panzenboeck, Ute
    Niederkofler, Vera
    Zimmermann, Robert
    Hutter-Paier, Birgit
    PLOS ONE, 2018, 13 (05):
  • [40] ALS/FTLD-linked TDP-43 regulates neurite morphology and cell survival in differentiated neurons
    Han, Jeong-Ho
    Yu, Tae-Hoon
    Ryu, Hyun-Hee
    Jun, Mi-Hee
    Ban, Byung-Kwan
    Jang, Deok-Jin
    Lee, Jin-A
    EXPERIMENTAL CELL RESEARCH, 2013, 319 (13) : 1998 - 2005